Trial Profile
A Phase II Study of SGI-110 in Philadelphia-Negative Myeloproliferative Neoplasms
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 May 2022
Price :
$35
*
At a glance
- Drugs Guadecitabine (Primary)
- Indications Chronic myeloid leukaemia; Chronic myelomonocytic leukaemia; Chronic neutrophilic leukaemia; Myelodysplastic syndromes; Myelofibrosis; Myeloproliferative disorders
- Focus Therapeutic Use
- 29 Jul 2021 Status changed from active, no longer recruiting to completed.
- 29 Mar 2021 Planned primary completion date changed from 19 Feb 2021 to 19 Feb 2022.
- 31 Mar 2020 Status changed from recruiting to active, no longer recruiting.